Axsome Therapeutics announced FDA approval of AUVELITY, a first-in-class oral treatment for agitation associated with dementia due to Alzheimer's disease. AUVELITY targets NMDA and sigma-1 receptors and was previously approved for major depressive disorder. The company held a virtual investor event featuring expert Dr. Jeffrey Cummings to discuss the drug's clinical benefits and commercial plans. This approval addresses a significant unmet need, as agitation affects up to 76% of Alzheimer's patients and contributes to faster cognitive decline and caregiver burden.
Entries for the Global Sustainability Awards 2026 close on June 29, recognizing excellence in sustainability across eight categories including enterprise, innovation, and environmental impact. The awards highlight businesses and individuals driving m...
Bio Usawa, a biotech firm focused on expanding access to biologic medicines in Africa, has appointed Dr. Aida Habtezion, former Chief Medical Officer at Pfizer, to its Board of Directors. Her expertise in global medical leadership and innovation will...
InterDigital, a leader in wireless, video, and AI technology, will present its latest innovations at the 13th FOKUS Media Web Symposium in Berlin, June 16-17, 2026. The company will demonstrate AI-enabled Pixel Value Reduction technology for energy-e...
Orange announced its intention to issue new perpetual hybrid bonds with a fixed adjustable interest rate and to launch a buyback offer for certain existing hybrid bonds. The new bonds are expected to be rated BBB-/Baa3/BBB- and traded on Euronext Par...
Orange announced its intention to issue new Euro-denominated hybrid notes with a 7-year non-call period and fixed-to-reset rates, expected to be rated BBB-/Baa3/BBB-. Simultaneously, the company is launching a tender offer to repurchase some of its o...
